Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin BI 907828 treatment in patients with treatment-na�ve or pre-treated advanced dedifferentiated liposarcoma
Study Type: Treatment
Phase: III
NCTID: NCT06058793
Principal Investigator:
Benjamin Powers
Randomized Phase II Trial Evaluation the Addition of the IGF-1R Monoclonal Antibody Receptor Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Study Type: Treatment
Phase: II
NCTID: NCT02306161
Principal Investigator:
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas PAZNTIS: A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minues Pazopanib NSC 737754, IND 118613
Study Type: Treatment
Phase: II/III
NCTID: NCT02180867
Principal Investigator:
Single Person IND for the Use of TK216 in a patient with metastatic Ewing sarcoma
Study Type: Treatment
Phase: N/A
NCTID: NCT00000000
Principal Investigator:
Benjamin Powers
A Phase IB Trial of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma STS
Study Type: Treatment
Phase: I
NCTID: NCT03217266
Principal Investigator:
Benjamin Powers
A Phase 2 Study of DS-8201a NSC 807708 in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma
Study Type: Treatment
Phase: II
NCTID: NCT04616560
Principal Investigator:
Kevin Ginn
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk Retroperitoneal Sarcoma STRASS2
Study Type: Treatment
Phase: III
NCTID: NCT04031677
Principal Investigator:
Luke Selby
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial
Study Type: Treatment
Phase: II
NCTID: NCT04347122
Principal Investigator:
Kyle Sweeney
A Phase I/II Open-Label Trial of CPI-613� devimistat plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose MTD, Safety and Efficacy in Patients with Relapsed or Refractory Clear Cell Sarcoma CCS
Study Type: Treatment
Phase: I/II
NCTID: NCT04593758
Principal Investigator:
Benjamin Powers
A Multicenter, Randomized, Placebo-controlled, Double-blind Study of DCC-3014 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor
Study Type: Treatment
Phase: III
NCTID: NCT05059262
Principal Investigator:
Benjamin Powers